Cara Therapeutics, Inc. (CARA)
15.96
-0.69 (-4.14%)
Inactive · Last trade price on Apr 15, 2025
Cara Therapeutics Revenue
In the year 2024, Cara Therapeutics had annual revenue of $7.14M, down -65.96%. Cara Therapeutics had revenue of $1.46M in the quarter ending December 31, 2024, a decrease of -51.56%.
Revenue (ttm)
$7.14M
Revenue Growth
-65.96%
P/S Ratio
3.40
Revenue / Employee
$713,700
Employees
10
Market Cap
24.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.14M | -13.83M | -65.96% |
| Dec 31, 2023 | 20.97M | -20.90M | -49.92% |
| Dec 31, 2022 | 41.87M | 18.84M | 81.81% |
| Dec 31, 2021 | 23.03M | -112.05M | -82.95% |
| Dec 31, 2020 | 135.08M | 115.20M | 579.28% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCARA News
- 6 months ago - Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics - GlobeNewsWire
- 6 months ago - Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics - GlobeNewsWire
- 8 months ago - CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA - Business Wire
- 10 months ago - Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split - GlobeNewsWire
- 11 months ago - Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement - GlobeNewsWire
- 1 year ago - These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers' - Benzinga
- 1 year ago - Cara Therapeutics discontinues study on a neurological condition as drug fails - Reuters
- 1 year ago - Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica - GlobeNewsWire